Amid the ongoing COVID-19 pandemic, it has become increasingly important to monitor the mutations that arise in the SARS-CoV-2 virus, to prepare public health strategies and guide the further development of vaccines and therapeutics. The spike (S) protein and the proteins comprising the RNA-Dependent RNA Polymerase (RdRP) are key vaccine and drug targets, respectively, making mutation surveillance of these proteins of great importance. Full protein sequences for the spike proteins and RNA-dependent RNA polymerase proteins were downloaded from the GISAID database, aligned, and the variants identified. Polymorphisms in the protein sequence were investigated at the protein structural level and examined longitudinally in order to identify sequence and strain variants that are emerging over time. Our analysis revealed a group of variants in the spike protein and the polymerase complex that appeared in August, and account for around five percent of the genomes analyzed up to the last week of October. A structural analysis also facilitated investigation of several unique variants in the receptor binding domain and the N-terminal domain of the spike protein, with high-frequency mutations occurring more commonly in these regions. The identification of new variants emphasizes the need for further study on the effects of these mutations and the implications of their increased prevalence, particularly as these mutations may impact vaccine or therapeutic efficacy.

Background: The increasing incidence of drug resistance in tuberculosis and other infectious diseases poses an escalating cause for concern, emphasizing the urgent need to devise robust computational and molecular methods identify drug resistant strains. Although machine learning-based approaches using whole-genome sequence data can facilitate the inference of drug resistance, current implementations do not optimally take advantage of information in public databases and are not robust for small sample sizes and mixed attribute types. Results: In this paper we introduce the Composite MetaDistance method, an approach for feature selection and classification of high-dimensional, unbalanced datasets with mixed attribute features from various data sources. We introduce a mixed-attribute, multi-view distance function to calculate distances between samples, with optimal handling of nominal features and different feature views. We also introduce a novel feature set for drug resistance prediction in Mycobacterium tuberculosis, using data from diverse sources. We compare the performance of Composite MetaDistance to multiple machine learning algorithms for Mycobacterium tuberculosis drug resistance prediction for three drugs. Composite MetaDistance consistently outperforms existing algorithms for small sample training sets, and performs as well as other algorithms for training sets with larger sample sizes. Conclusion: The feature set formulation introduced in this paper is utilizes mutational and publicly available information for each gene, and is much richer than ever devised previously. The prediction algorithm, Composite MetaDistance, is sample size agnostic and robust especially given small sample sizes. Proper handling of nominal features improves performance even with a very small number of nominal features. We expect Composite MetaDistance to be even more robust for datasets with a higher percentage of nominal features. The algorithm is application independent and can be used for any mixed attribute dataset.